Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F21%3A00119761" target="_blank" >RIV/00216224:14160/21:00119761 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3933/3844" target="_blank" >http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3933/3844</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

čeština

Název v původním jazyce

Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté

Popis výsledku v původním jazyce

Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.

Název v anglickém jazyce

Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists

Popis výsledku anglicky

Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/QK1810221" target="_blank" >QK1810221: Využití mikročástic jako nosičů hormonálně aktivních látek v řízené reprodukci ryb.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CHEMICKÉ LISTY

ISSN

0009-2770

e-ISSN

1213-7103

Svazek periodika

115

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

516-523

Kód UT WoS článku

000708686300004

EID výsledku v databázi Scopus

—